Alumis (ALMS) Assets Average (2024 - 2025)
Alumis (ALMS) reported Assets Average of $450.0 million for Q4 2025, up 19.43% year-over-year from $376.8 million in Q4 2024, and down 18.11% on a QoQ basis from $549.5 million in Q3 2025.
Alumis (ALMS) has 2 years of Assets Average data on file, last reported at $450.0 million in Q4 2025.
- Quarterly Assets Average rose 19.43% year-over-year to $450.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $450.0 million (up 19.43% YoY) and the FY2025 annual result came in at $376.5 million, up 74.85% from the prior year.
- Assets Average fell to $450.0 million in Q4 2025 per ALMS's latest filing, from $549.5 million in the prior quarter.
- Across five years, Assets Average topped out at $549.5 million in Q3 2025 and bottomed at $301.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | 449.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 449.98 Mn |
| Sep 30, 2025 | 549.47 Mn |
| Jun 30, 2025 | 436.11 Mn |
| Mar 31, 2025 | 301.15 Mn |
| Dec 31, 2024 | 376.78 Mn |
| Sep 30, 2024 | 338.87 Mn |